Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.84
-0.64 (-0.99%)
At close: Mar 28, 2025, 4:00 PM
63.00
-0.84 (-1.32%)
After-hours: Mar 28, 2025, 6:54 PM EDT

Company Description

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.

The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc.
Halozyme Therapeutics logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 350
CEO Helen Torley

Contact Details

Address:
12390 El Camino Real
San Diego, California 92130
United States
Phone 858 794 8889
Website halozyme.com

Stock Details

Ticker Symbol HALO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001159036
CUSIP Number 40637H109
ISIN Number US40637H1095
Employer ID 88-0488686
SIC Code 2836

Key Executives

Name Position
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. President, Chief Executive Officer and Director

Latest SEC Filings

Date Type Title
Mar 21, 2025 8-K Current Report
Mar 18, 2025 ARS Filing
Mar 18, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 18, 2025 DEF 14A Other definitive proxy statements
Feb 25, 2025 144 Filing
Feb 18, 2025 10-K Annual Report
Feb 18, 2025 8-K Current Report
Feb 13, 2025 8-K Current Report
Feb 3, 2025 144 Filing
Jan 8, 2025 8-K Current Report